Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites
Condition(s) studied
Investigational drug(s) / intervention(s)
ZhenQi FuZheng granules (ShiDaiYangGuang): 1 bag at a time, twice a day. Oral orally for 4 weeks.
Study summary
ZhenQi FuZheng granules has been used to improve the immune function of human body, protect the bone marrow and adrenal cortex function and promote the recovery of positive function in traditional Chinese medicine care, especially with the immune imbalance diseases like post-surgery, chemotherapy and rhinitis. This project intends to establish AR(allergic rhinitis)specimen library, cell and animal model experiment, combining clinical cohort research with applied basic research, further assess the therapeutic mechanism of ZhenQiFuZheng granules in AR. We assume that ZhenQi FuZheng granules could cause the metabolic omics changes of nasal inflammatory factors and nasal secretions in AR patients, thus improving the type 2 inflammation level of allergic rhinitis.
Eligibility
Primary outcome measure(s)
- Rhinoconjunctivitis Quality of Life Questionnaire — 12 weeks
Patients were scored by questionnaire before and after treatment, and the change in score before and after treatment was the primary outcome measure - Visual Analog Score for pain — 12 weeks
Patients were scored by questionnaire before and after treatment, and the change in score before and after treatment was the primary outcome measure
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital with Nanjing Medical University | Nanjing | Jiangsu | Recruiting |
More The First Affiliated Hospital with Nanjing Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06427577 on ClinicalTrials.gov ↗ ← All trials in China